Spots Global Cancer Trial Database for A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod and Other Therapy Combinations in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod and Other Therapy Combinations in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Official Title: A Phase 1b, Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod and Other Therapy Combinations in Subjects With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Study ID: NCT04196283
Conditions
Study Description
Brief Summary: The main objective of this study is to assess safety, tolerability, and pharmacokinetics (PK) of ABBV-368 plus tilsotolimod; ABBV-368 plus tilsotolimod and nab-paclitaxel; and ABBV-368 plus tilsotolimod, nab-paclitaxel, and ABBV-181 in participants with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
The University of Chicago Medical Center /ID# 217196, Chicago, Illinois, United States
Norton Cancer Institute /ID# 216179, Louisville, Kentucky, United States
Barbara Ann Karmanos Cancer In /ID# 214050, Detroit, Michigan, United States
Nebraska Methodist Hospital /ID# 215786, Omaha, Nebraska, United States
Atlantic Health System /ID# 216159, Morristown, New Jersey, United States
Roswell Park Comprehensive Cancer Center /ID# 215882, Buffalo, New York, United States
Vanderbilt Ingram Cancer Center /ID# 214040, Nashville, Tennessee, United States
MD Anderson Cancer Center /ID# 214041, Houston, Texas, United States
Centre Antoine Lacassagne - Nice /ID# 215706, Nice, Alpes-Maritimes, France
AP-HM - Hopital de la Timone /ID# 215657, Marseille CEDEX 05, Bouches-du-Rhone, France
Hopital Saint-Andre /ID# 215702, Bordeaux, Gironde, France
Institut Curie /ID# 215653, Paris CEDEX 05, Ile-de-France, France
Universitaetsklinikum Erlangen /ID# 214196, Erlangen, Bayern, Germany
Universitaetsklinikum Leipzig /ID# 214200, Leipzig, Sachsen, Germany
Charite Universitaetsklinikum Berlin - Campus Benjamin Franklin /ID# 214197, Berlin, , Germany
The Chaim Sheba Medical Center /ID# 215229, Ramat Gan, Tel-Aviv, Israel
Rambam Health Care Campus /ID# 215231, Haifa, , Israel
Gastroenterology Institute, Division of Medicine /ID# 215862, Jerusalem, , Israel
Antoni van Leeuwenhoek /ID# 215291, Amsterdam, Noord-Holland, Netherlands
Instituto Catalan de Oncologia (ICO) L'Hospitalet /ID# 221402, Hospitalet de Llobregat, Barcelona, Spain
Hospital Universitario de Fuenlabrada /ID# 214263, Fuenlabrada, Madrid, Spain
Hospital Clinic de Barcelona /ID# 214264, Barcelona, , Spain
Hospital Universitario 12 de Octubre /ID# 214198, Madrid, , Spain
Hospital Universitario HM Sanchinarro /ID# 214110, Madrid, , Spain
Hospital Universitario Virgen de la Victoria /ID# 214109, Malaga, , Spain
Hospital Clinico Universitario de Valencia /ID# 221401, Valencia, , Spain
Contact Details
Name: ABBVIE INC.
Affiliation: AbbVie
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
